imaprelimab (PRX003) / Prothena - LARVOL DELTA

CD146+ pericyte-like lung cancer brain metastatic stem cells promote tumor angiogenesis through dual regulatory effects on the VEGF/VEGFR axis. (PubMed, Theranostics) - "However, bevacizumab (Bev) shows limited therapeutic effects on NSCLC BrM...Targeting CD146 by imaprelimab or AXL by bemcentinib exhibits more effective anti-angiogenic effects than Bev for BrM in vivo. These findings provide novel anti-vascular strategies for BrM. CD146+ BrM-CSCs promotes high vascularization of lung cancer brain metastases through dual enhancement of VEGF/VEFGR, which suggests that targeting CD146 is a novel anti-vascular strategy for BrM."

Journal • Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • AXL • GAS6 • KDR • MCAM

CD146 Promotes Tumor Angiogenesis Through Dual Regulatory Effects on the VEGF/VEGFR Axis and as a Potent Target for Anti-vascular Therapies in Lung Cancer Brain Metastasis (ATS 2025) - "Drugs targeting AXL (bemcentinib) and CD146 (imaprelimab) effectively exhibited anti-vascular efficacy against BM alone and in combination with bevacizumab in vivo. CONCLUSIONOur work reveals that CD146 promotes high vascularization of lung cancer brain metastases through dual enhancement of VEGF/VEFGR, which suggests that targeting CD146 is an alternative anti-vascular strategy to bevacizumab in the treatment of NSCLC BM."

Brain Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • AXL • GAS6 • KDR • MCAM

Prothena to present preclinical data for PRX003 at 2016 AAAAI annual meeting (GlobeNewswire) - "Prothena Corporation...today announced that preclinical data from its PRX003 program will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2016 Annual Meeting to be held March 4-7, 2016 in Los Angeles, CA...(Abstract #24545) Anti-MCAM Monoclonal Antibody PRX003 Inhibits the Unique Migratory Potential of Pathogenic IL-17–Producing T Cells."

Anticipated conference • Anticipated preclinical • Psoriasis

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis (clinicaltrials.gov) - P1; N=48; Completed; Sponsor: Prothena Biosciences Limited; Recruiting ➔ Completed; Trial primary completion date: Aug 2017 ➔ Feb 2018

Trial completion • Trial primary completion date • Biosimilar • Dermatology • Immunology • Psoriasis

Prothena reports results of phase 1 single ascending dose study of PRX003, demonstrating target engagement of the novel anti-MCAM antibody for inflammatory diseases (GlobeNewswire) - P1, N=40; NCT02458677; "Prothena Corporation...today announced new clinical results from a Phase 1 double blind, placebo controlled, single ascending dose study of PRX003 in healthy volunteers...The data, being presented on June 10th at 11:20 AM BST in an oral session at The European League Against Rheumatism (EULAR) 17th Annual European Congress of Rheumatology in London, demonstrated that PRX003 was safe and well-tolerated following a single infusion, up to and including the highest dose level tested of 30 mg/kg...Data from this study is expected in the second half of 2017."

Anticipated P1 data • Conference • P1 data • Inflammation • Psoriasis